Tracking blood cancer treatment: can this drug control symptoms and reduce complications?
NCT ID NCT06743035
Summary
This study follows 200 adults with polycythemia vera (a blood cancer causing too many red blood cells) who are taking ropeginterferon alfa-2b in real-world German clinics. Researchers will track patients' symptom burden, how well the drug controls blood counts, and safety over three years. The goal is to understand how this treatment performs outside of controlled trials and its impact on patients' daily lives.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Onkologisches Studienzentrum Dr. med. Ingo Zander & Dr. med. Eyck von der Heyde
RECRUITINGHanover, Lower Saxony, 30161, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.